GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (FRA:CN2) » Definitions » Cyclically Adjusted Price-to-FCF

Catalyst Pharmaceuticals (FRA:CN2) Cyclically Adjusted Price-to-FCF : 72.58 (As of May. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Catalyst Pharmaceuticals Cyclically Adjusted Price-to-FCF?

As of today (2024-05-26), Catalyst Pharmaceuticals's current share price is €14.515. Catalyst Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.20. Catalyst Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is 72.58.

The historical rank and industry rank for Catalyst Pharmaceuticals's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

FRA:CN2' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 70.1   Med: 119.69   Max: 1477
Current: 75.04

During the past years, Catalyst Pharmaceuticals's highest Cyclically Adjusted Price-to-FCF was 1477.00. The lowest was 70.10. And the median was 119.69.

FRA:CN2's Cyclically Adjusted Price-to-FCF is ranked worse than
62.5% of 104 companies
in the Biotechnology industry
Industry Median: 54.85 vs FRA:CN2: 75.04

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Catalyst Pharmaceuticals's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €0.237. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €0.20 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Catalyst Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Catalyst Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 200.67 95.17

Catalyst Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 148.17 92.08 97.31 95.17 75.37

Competitive Comparison of Catalyst Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Catalyst Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Catalyst Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=14.515/0.2
=72.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Catalyst Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.237/131.7762*131.7762
=0.237

Current CPI (Mar. 2024) = 131.7762.

Catalyst Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.033 100.560 -0.043
201409 -0.041 100.428 -0.054
201412 -0.047 99.070 -0.063
201503 -0.046 99.621 -0.061
201506 -0.046 100.684 -0.060
201509 -0.058 100.392 -0.076
201512 -0.051 99.792 -0.067
201603 -0.064 100.470 -0.084
201606 -0.047 101.688 -0.061
201609 -0.035 101.861 -0.045
201612 -0.050 101.863 -0.065
201703 -0.044 102.862 -0.056
201706 -0.034 103.349 -0.043
201709 -0.026 104.136 -0.033
201712 -0.037 104.011 -0.047
201803 -0.048 105.290 -0.060
201806 -0.040 106.317 -0.050
201809 -0.058 106.507 -0.072
201812 -0.071 105.998 -0.088
201903 -0.069 107.251 -0.085
201906 0.117 108.070 0.143
201909 0.138 108.329 0.168
201912 0.104 108.420 0.126
202003 0.061 108.902 0.074
202006 0.110 108.767 0.133
202009 0.091 109.815 0.109
202012 0.102 109.897 0.122
202103 0.023 111.754 0.027
202106 0.121 114.631 0.139
202109 0.171 115.734 0.195
202112 0.156 117.630 0.175
202203 0.071 121.301 0.077
202206 0.227 125.017 0.239
202209 0.372 125.227 0.391
202212 0.331 125.222 0.348
202303 0.098 127.348 0.101
202306 0.250 128.729 0.256
202309 -0.301 129.860 -0.305
202312 0.430 129.419 0.438
202403 0.237 131.776 0.237

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Catalyst Pharmaceuticals  (FRA:CN2) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Catalyst Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals (FRA:CN2) Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals (FRA:CN2) Headlines

No Headlines